FDA denies Unicycive's NDA for Oxylanthanum Carbonate due to vendor issues; company eyes quick resolution with alternate ...

Unicycive Therapeutics has hit a bump on the road in its mission to bring its hyperphosphatemia treatment candidate to ...

By adopting FDA-endorsed endpoints that are easier to achieve, Dimerix has bolstered the chances of its pivotal kidney drug trial succeeding.

FDA issues a complete response letter for oxylanthanum carbonate, a treatment for hyperphosphatemia in patients with chronic ...

The 61-year-old man received a new kidney from a deceased donor after being diagnosed with “nephrosclerosis-related end-stage ...

Unicycive, which was seeking approval of oxylanthanum carbonate to treat hyperphosphatemia in patients with chronic kidney disease on dialysis, said the FDA issued a so-called complete response letter ...

One lot of reflux medicine got recalled when fluid retention tablets were discovered in the medicine bottles.

June 30, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. ("Unicycive” or the "Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney ...

BIIB begins phase III dosing of felzartamab primary membranous nephropathy study, targeting a tough-to-treat condition with ...

Riliprubart is an immunoglobulin G4 humanized antibody that is designed to selectively inhibit activated C1s in the classical complement pathway of the innate immune system.

Bayer has claimed EU approval for Kerendia, its new drug for chronic kidney disease (CKD) in people with type 2 diabetes, as the company tries to build a role of the drug alongside rival therapies ...

Vera Therapeutics Inc. (NASDAQ:VERA) is one of the best high short interest stocks with huge upside potential. Earlier in ...